The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions, current medications have several limitations, ...

Depression continues to grapple a large proportion of the population. Given the side effects associated with the long-term ...

Medically reviewed by Lindsay Cook, PharmD Vicodin (hydrocodone-acetaminophen) and Percocet (oxycodone-acetaminophen) are ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

We strive to develop medications that do only 1 or 2 things (ie, blocking serotonin reuptake or blocking D2 and 5HT2a receptors) and do nothing else. We assume that all other mechanisms of action ...

The global burden of anxiety- and depression-related disorders is on the rise. While multiple drugs have been developed to treat these conditions ...

Purpose. Published reports on placebo-controlled clinical trials and other studies investigating the use of pure opioid antagonists for the prevention and treatment of opioid-induced pruritus (OIP ...

Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Accordingly, opioid abuse has become a problem of epidemic proportions in the United States and throughout much of the world. The International Narcotics Research Conference has held annual meetings ...

Gilgamesh Pharmaceuticals is developing a diverse portfolio of novel, potentially first-in-class and best-in-class medicines targeting mechanisms ... target the κ-opioid receptor (KOR) among ...